Furosemide Price Trend, Index and Forecast

Track the latest insights on furosemide price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.

Furosemide Prices Outlook Q4 2025

• USA: USD 87060/MT
• China: USD 77977/MT
• Germany: USD 95408/MT
• India: USD 92121/MT
• Brazil: USD 97485/MT

Furosemide Price Chart

Get real-time access to monthly/quarterly/yearly prices 中国·银河贵宾汇(GALAXY):Request Sample

During the fourth quarter of 2025, the furosemide prices in the USA reached 87060 USD/MT in December. Prices increased supported by steady demand from generic pharmaceutical manufacturers and hospital procurement programs. Additionally, regulated production schedules and compliance-driven manufacturing standards influenced supply positioning, while buyers aligned sourcing with contractual healthcare distribution requirements. During the fourth quarter of 2025, the furosemide prices in China reached 77977 USD/MT in December. Prices declined as export-oriented bulk drug demand softened and downstream formulation activity moderated. Moreover, sufficient domestic production capacity and competitive supplier positioning shaped procurement behavior, encouraging cautious purchasing aligned with short-term manufacturing needs. During the fourth quarter of 2025, the furosemide prices in Germany reached 95408 USD/MT in December. Prices rose driven by firm demand from pharmaceutical formulation facilities and hospital supply chains. In addition to this, structured distributor agreements and stringent regulatory compliance influenced sourcing strategies across the healthcare sector. During the fourth quarter of 2025, the furosemide prices in India reached 92121 USD/MT in December. Prices moved lower influenced by moderated export demand and competitive pricing among active pharmaceutical ingredient producers. Furthermore, stable raw material availability and disciplined inventory management shaped procurement decisions across formulation manufacturers. During the fourth quarter of 2025, the furosemide prices in Brazil reached 97485 USD/MT in December. Prices advanced supported by consistent demand from domestic pharmaceutical producers and healthcare institutions. Apart from this, import reliance and logistics coordination influenced sourcing strategies, with buyers maintaining structured procurement aligned with regulatory requirements.

Furosemide Prices Outlook Q3 2025

• USA: USD 84664/MT
• China: USD 80671/MT
• Germany: USD 92620/MT
• India: USD 94107/MT
• Brazil: USD 94134/MT

During the third quarter of 2025, the furosemide prices in the USA reached 84664 USD/MT in September. Prices moved upward as demand from pharmaceutical formulators and hospital supply chains strengthened ahead of seasonal stocking cycles. Manufacturers faced tighter availability of key intermediates, while compliance-related production controls limited flexible output adjustments. Import inflows were moderated by quality audits and longer lead times, increasing reliance on domestic supply. During the third quarter of 2025, the furosemide prices in China reached 80671 USD/MT in September. Prices trended downward due to sufficient domestic production capacity and muted export inquiries from overseas generic drug manufacturers. Several producers operated at routine utilization rates, supported by stable access to raw materials. Inventory levels at manufacturing and distribution points remained adequate, reducing urgency among buyers. During the third quarter of 2025, the furosemide prices in Germany reached 92620 USD/MT in September. The market experienced upward pricing pressure driven by sustained demand from regulated pharmaceutical manufacturing and healthcare distribution networks. Producers operated under stringent quality and regulatory standards, which constrained rapid capacity adjustments. Limited import availability from non-EU sources increased dependence on regional suppliers. During the third quarter of 2025, the furosemide prices in India reached 94107 USD/MT in September. Prices increased as domestic and export-oriented pharmaceutical manufacturers maintained strong production schedules. Demand from formulation units and contract manufacturing organizations remained active. Raw material sourcing experienced tighter availability, influencing cost structures. During the third quarter of 2025, the furosemide prices in Brazil reached 94134 USD/MT in September. Prices moved lower due to adequate import availability and moderated demand from public healthcare procurement channels. Distributors managed inventories conservatively, aligning purchases with near-term requirements. Import sourcing from Asia remained accessible, increasing supplier competition.

Furosemide Prices Outlook Q2 2025

• USA: USD 81960/MT
• China: USD 82150/MT
• Germany: USD 91072/MT
• India: USD 91278/MT
• Brazil: USD 96647/MT

During the second quarter of 2025, the furosemide prices in the USA reached 81960 USD/MT in June. Pricing during this period reflected pharmaceutical demand planning and supplier contract renewals. Manufacturing schedules aligned with hospital procurement cycles influenced order placements. Regulatory compliance costs and quality testing requirements shaped supplier pricing models. Domestic logistics coordination and warehousing considerations affected distribution economics. During the second quarter of 2025, the furosemide prices in China reached 82150 USD/MT in June. Market conditions were influenced by production planning at API facilities and raw material sourcing coordination. Environmental compliance requirements shaped operational decisions. Export commitments and domestic pharmaceutical demand required careful allocation strategies. During the second quarter of 2025, the furosemide prices in Germany reached 91072 USD/MT in June. Pricing reflected adherence to strict pharmaceutical standards and validation protocols. Energy procurement planning and sustainability obligations influenced production economics. Import coordination for intermediates required careful logistics management. Healthcare reimbursement frameworks and distributor contracts shaped purchasing behavior. During the second quarter of 2025, the furosemide prices in India reached 91278 USD/MT in June. Pricing trends were shaped by export-oriented production planning and domestic formulation demand. Procurement of intermediates required coordination across supplier networks. Regulatory inspections and documentation requirements influenced operational timelines. During the second quarter of 2025, the furosemide prices in Brazil reached 96647 USD/MT in June. Pricing reflected dependence on international suppliers and customs processing requirements. Public healthcare procurement frameworks influenced demand visibility. Inventory planning across distribution networks shaped purchasing schedules. Regulatory approvals and quality compliance added administrative considerations.

Regional Coverage

The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing the furosemide prices.

Europe Furosemide Price Trend

Q4 2025:

As per the furosemide price index, European prices moved upward reflecting firm demand from pharmaceutical formulation plants and structured hospital procurement systems. Additionally, compliance with stringent EU GMP standards and batch traceability requirements influenced production scheduling and distributor pricing strategies. Parallel trade regulations and cross-border supply coordination further shaped market dynamics. Buyers emphasized long-term supply agreements and regulatory assurance, aligning procurement closely with institutional healthcare demand and national reimbursement frameworks.

Q3 2025:

Furosemide price index trends in Europe were shaped by regulatory compliance intensity, energy cost exposure, and pharmaceutical quality standards. Manufacturers operated within tightly controlled frameworks requiring extensive documentation and validation. Import coordination for active pharmaceutical ingredients influenced supply planning. Sustainability requirements and waste management obligations affected operational cost structures. Distribution across national healthcare systems required stable contractual arrangements. These factors collectively framed regional pricing conditions.

Q2 2025:

During the second quarter of 2025, furosemide price index trends were influenced by rigorous pharmaceutical compliance standards and multilayered regulatory oversight across the region. Manufacturers operated within strict validation and audit frameworks that required continuous monitoring of production quality, documentation accuracy, and traceability. Energy procurement planning played a significant role in shaping operational cost considerations, as producers aligned sourcing strategies with long-term sustainability and efficiency objectives. This analysis can be extended to include detailed furosemide price information for a comprehensive list of countries.

Region	Countries Covered
Europe	Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece, among other European countries.

North America Furosemide Price Trend

Q4 2025:

As per the furosemide price index, prices in North America increased supported by steady demand from generic drug manufacturers and hospital purchasing organizations. Furthermore, regulatory compliance under FDA oversight and stable API production cycles influenced supply positioning. Group purchasing organizations and contract manufacturing arrangements played a significant role in procurement planning. Buyers maintained structured sourcing strategies to ensure uninterrupted supply across retail pharmacy chains and institutional healthcare networks.

Q3 2025:

Furosemide price index behavior in North America reflected healthcare procurement models, regulatory oversight, and supply chain coordination. Pharmaceutical manufacturers aligned production with hospital demand forecasting. Quality assurance investments influenced supplier cost structures. Domestic logistics planning and inventory management shaped transactional dynamics. Contractual sourcing frameworks supported market stability across the region.

Q2 2025:

Furosemide price index behavior in North America reflected disciplined procurement planning and heightened regulatory oversight within the pharmaceutical sector. Manufacturers closely aligned production schedules with healthcare demand forecasting models used by hospitals and distributors. Regulatory compliance requirements related to manufacturing practices, quality assurance, and traceability influenced operational frameworks and supplier cost structures. Investments in quality compliance systems, testing protocols, and certification processes shaped pricing structures across the supply chain. Specific furosemide historical data within the United States and Canada can also be provided.

Region	Countries Covered
North America	United States and Canada

Middle East and Africa Furosemide Price Trend

Q4 2025:

As per furosemide price chart, the prices in the Middle East and Africa fluctuated due to a complex interplay of factors, primarily driven by supply chain disruptions, seasonal demand shifts, and geopolitical influences.

Q3 2025:

The report explores the furosemide pricing trends and furosemide price chart in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices. In addition to region-wise data, information on furosemide prices for countries can also be provided.

Region	Countries Covered
Middle East & Africa	Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco, among other Middle Eastern and African countries.

Asia Pacific Furosemide Price Trend

Q4 2025:

Across Asia Pacific, furosemide prices moved downward, influenced by softened export demand from bulk active pharmaceutical ingredient manufacturers and moderated formulation activity across key production hubs. Additionally, competitive supplier positioning and stable raw material availability reduced pricing pressure. Buyers adjusted procurement volumes conservatively, prioritizing short-term production visibility and inventory rationalization across pharmaceutical manufacturing centers.

Q3 2025:

Asia Pacific pricing dynamics reflected a complex interaction between concentrated pharmaceutical manufacturing bases, export-oriented production strategies, and diverse regulatory environments across countries. Major API production hubs operated under capacity optimization frameworks to align output with both domestic pharmaceutical formulation requirements and overseas contractual obligations. Regulatory diversity across the region required suppliers to maintain multiple compliance standards, influencing production planning and documentation workflows.

Q2 2025:

During the second quarter of 2025, Asia Pacific pricing trends reflected large-scale pharmaceutical manufacturing activity, strong export orientation, and regulatory diversity across national markets. API producers balanced domestic pharmaceutical formulation demand with international contract manufacturing commitments, requiring coordinated production planning. Regulatory diversity across the region necessitated adherence to multiple compliance standards, influencing documentation and operational workflows. This furosemide price analysis can be expanded to include a comprehensive list of countries within the region.

Region	Countries Covered
Asia Pacific	China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries.

Latin America Furosemide Price Trend

Q4 2025:

Regional market assessments across Latin America indicated an upward pricing trend for furosemide supported by steady demand from domestic pharmaceutical manufacturers and expanding public healthcare coverage. Additionally, import licensing requirements and currency considerations influenced procurement strategies. Buyers aligned sourcing decisions with government tender cycles, hospital distribution frameworks, and regulatory approval timelines to ensure consistent supply for cardiovascular treatment programs.

Q3 2025:

Latin American furosemide pricing was shaped by a strong reliance on imported active pharmaceutical ingredients and region-specific healthcare procurement mechanisms. Import dependency placed emphasis on customs clearance efficiency, documentation accuracy, and supplier qualification processes. Healthcare procurement structures, particularly public sector tender systems, guided purchasing volumes and contract timelines. Logistics infrastructure limitations influenced distribution planning and inventory positioning across domestic markets.

Q2 2025:

Latin American pricing behavior was influenced by continued import dependency and region-specific healthcare procurement structures. Regulatory documentation requirements related to pharmaceutical registration, quality compliance, and labeling influenced supplier approval timelines. Inventory planning strategies were closely aligned with demand visibility from both public and private healthcare sectors. Logistics coordination across domestic transportation networks affected distribution efficiency and supplier engagement. This comprehensive review can be extended to include specific countries within the region.

Region	Countries Covered
Latin America	Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru, among other Latin American countries.

Furosemide Pricing Report, Market Analysis, and News

IMARC's latest publication, “Furosemide Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2026 Edition,” presents a detailed examination of the furosemide market, providing insights into both global and regional trends that are shaping prices. This report delves into the spot price of furosemide at major ports and analyzes the composition of prices, including FOB and CIF terms. It also presents detailed furosemide prices trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors affecting furosemide pricing, such as the dynamics of supply and demand, geopolitical influences, and sector-specific developments, are thoroughly explored. This comprehensive report helps stakeholders stay informed with the latest market news, regulatory updates, and technologicඣal progress, facilitating informed strategic decision-making a🃏nd forecasting.

Furosemide Industry Analysis

The global furosemide market size reached USD 1,035.2 Million in 2025. By 2034, IMARC Group expects the market to reach USD 1,503.3 Million, at a projected CAGR of 4.23% during 2026-2034. The market is primarily driven by the sustained demand from cardiovascular and renal treatment applications, expanding healthcare infrastructure, regulatory emphasis on quality compliance, and strong 💦pharmaceutical manufacturing activity.

Latest News and Developments:

• October 2025: Ligand Pharmaceuticals’ partner SQ Innovation received U.S. FDA approval for Lasix ONYU (furosemide injection), an at-home subcutaneous treatment for edema associated with heart failure. The wearable delivery system allows patients to administer furosemide outside hospital settings, aiming to reduce hospitalizations and support outpatient management of fluid overload.

Product Description

Furosemide is known as a potent loop medication utilized to treat edema caused due to liver disease, heart failure, and kidney disorders. By inhibiting the reabsorption of sodium and chloride ions in kidneys, it works efficiently to treat several diseases by increasing the urine flow and enabling the body to release excess fluid. Primarily used to manage chronic kidney disease, it is also used to treat congestive heart failure, where complications are caused by fluid generation. By reducing the volume of blood pumped by the heart, it is highly valuable in managing high blood pressure. Its availability in oral and intravenous forms, makes it highly preferable for both outpatient and inpatient facilities. The long-term treatment utilizes its oral form, while the intravenous form is used in acute situations. The report provides a detailed analysis of the furosemide market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of ex-works, FOB, and CIF prices, as well as the key factors influencing the furosemide price trend. 

Report Coverage

Key Attributes	Details
Product Name	Furosemide
Report Features	Exploration of Historical Trends and Market Outlook, Industry Demand, Industry Supply, Gap Analysis, Challenges, Furosemide Price Analysis, and Segment-Wise Assessment.
Currency/Units	US$ (Data can also be provided in local currency) or Metric Tons
Region/Countries Covered	The current coverage includes analysis at the global and regional levels only.    Based on your requirements, we can also customize the report and provide specific information for the following countries:    Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand*   Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece*    North America: United States and Canada Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru* Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco* *The list of countries presented is not exhaustive. Information on additional countries can be provided if required by the client.
Information Covered for Key Suppliers	Company Overview Business Description Recent Trends and Developments
Customization Scope	The report can be customized as per the requirements of the customer
Report Price and Purchase Option	Plan A: Monthly Updates - Annual Subscription Scope Historical Data for the Current Month Forecast for Next Month Total Deliverables Per Year: 12 (One Per Month) Includes: One PDF and Excel datasheet per month, Post Purchase Analyst Support throughout the year Plan B: Quarterly Updates - Annual Subscription Scope Historical Data for the Current Quarter Forecast for Next Quarter Total Deliverables Per Year: 4 (One Per Quarter) Includes: One PDF and Excel datasheet per Quarter, Post Purchase Analyst Support throughout the year Plan C: Biannually Updates - Annual Subscription Scope Historical Data for the Current Half Forecast for the Next Half Total Deliverables Per Year: 2 (One Per 6 Months) Includes: One PDF and Excel datasheet per Half, Post Purchase Analyst Support throughout the year
Post-Sale Analyst Support	360-degree analyst support after report delivery
Delivery Format	PDF and Excel through email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Benefits for Stakeholders:

• IMARC’s report presents a detailed analysis of furosemide pricing, covering global and regional trends, spot prices at key ports, and a breakdown of Ex Works, FOB, and CIF prices.
• The study examines factors affecting furosemide price trend, including raw material costs, supply-demand shifts, geopolitical impacts, and industry developments, offering insights for informed decision-making.
• The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
• IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The furosemide price charts ensure our clients remain at the forefront of the industry.